Literature DB >> 2140730

KIH-802, an acetohydroxamic acid derivative of 2-nitroimidazole, as a new potent hypoxic cell radiosensitizer: radiosensitizing activity, acute toxicity, and pharmacokinetics.

K Sasai1, Y Shibamoto, M Takahashi, L Zhou, H Hori, H Nagasawa, T Shibata, S Inayama, M Abe.   

Abstract

The radiosensitizing activity, acute toxicity, and pharmacokinetics of a new hypoxic cell radiosensitizer, potassium 2-nitroimidazole-1-acetohydroxamate (KIH-802), were compared with those of misonidazole (MISO) and etanidazole (SR-2508). The radiosensitizing activity of KIH-802 was slightly higher than that of MISO and SR-2508 in vitro and was similar to or slightly higher than that of MISO or SR-2508 in vivo. The acute toxicity of KIH-802 was slightly higher than that of MISO. The concentrations of KIH-802 in the brains and peripheral nerves of mice were as low as those of SR-2508 and lower than those of MISO.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2140730     DOI： 10.1007/bf02897255

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  18 in total

1.  Design of potent reversible inhibitors for thermolysin. Peptides containing zinc coordinating ligands and their use in affinity chromatography.

Authors:  N Nishino; J C Powers
Journal:  Biochemistry       Date:  1979-10-02       Impact factor: 3.162

2.  Misonidazole-a drug for trial in radiotherapy and oncology.

Authors:  S Dische; M I Saunders; I R Flockhart; M E Lee; P Anderson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-06       Impact factor: 7.038

3.  An in vitro and in vivo screening system for new hypoxic cell radiosensitizers using EMT6 cells.

Authors:  Y Shibamoto; K Ono; M Takahashi; E Kano; H Hori; T Shibata; S Inayama; M Abe
Journal:  Jpn J Cancer Res       Date:  1986-10

4.  The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole.

Authors:  R A White; P Workman; J M Brown
Journal:  Radiat Res       Date:  1980-12       Impact factor: 2.841

5.  Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule.

Authors:  C N Coleman; T H Wasserman; R C Urtasun; J Halsey; V K Hirst; S Hancock; T L Phillips
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-07       Impact factor: 7.038

6.  Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.

Authors:  C N Coleman; R C Urtasun; T H Wasserman; S Hancock; J W Harris; J Halsey; V K Hirst
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-09       Impact factor: 7.038

7.  The radiation response of SCCVII tumor cells in C3H/He mice varies with the irradiation conditions.

Authors:  Y Shibamoto; K Sasai; M Abe
Journal:  Radiat Res       Date:  1987-02       Impact factor: 2.841

8.  Evaluation of various types of new hypoxic cell sensitizers using the EMT6 single cell-spheroid-solid tumour system.

Authors:  Y Shibamoto; S Nishimoto; F Mi; K Sasai; T Kagiya; M Abe
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1987-09

9.  Variation in tumor response to fluosol-DA (20%).

Authors:  K Sasai; K Ono; T Nishidai; K Tsutsui; Y Shibamoto; M Takahashi; M Abe
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-05       Impact factor: 7.038

10.  In vitro and in vivo radiosensitizing effects of 2-nitroimidazole derivatives with sugar component.

Authors:  C Murayama; N Tanaka; Y Miyamoto; M Sakaguchi; T Mori
Journal:  Strahlenther Onkol       Date:  1987-06       Impact factor: 3.621
View more
  1 in total

1.  Low-dose ionizing radiation exposure represses the cell cycle and protein synthesis pathways in in vitro human primary keratinocytes and U937 cell lines.

Authors:  Kazumasa Sekihara; Kaori Saitoh; Haeun Yang; Haruki Kawashima; Saiko Kazuno; Mika Kikkawa; Hajime Arai; Takashi Miida; Nobuhiro Hayashi; Keisuke Sasai; Yoko Tabe
Journal:  PLoS One       Date:  2018-06-18       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.